Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 8001996

Peak component latency-corrected average method for evoked potential waveform estimation.

X H Yu·Y S Zhang·Z Y He
View original source ↗Export metadata ↓

Abstract

A peak component latency-corrected average (PC-LCA) method consisting of three steps is presented for estimating the evoked potentials (EP) in the human brain. The present PC-LCA is essentially an alternative version of the original LCA method developed by McGillem et al. It first uses a time-varying adaptive filter as a preprocessor to suppress the ongoing EEG and to enhance the EP. Then, the statistics of mean latencies and amplitudes of the EP peak components are estimated by a peak detection and alignment procedure. The final waveform estimate is obtained by superimposing the estimated mean peak components on background information and subsequently fitting a truncated Fourier series using the fast Fourier transform (FFT). Consistent estimates of the EP peak component information are established based on asymptotic analysis of the PC-LCA. Finally, real-time implementation of the PC-LCA is considered, and the superior performance of the PC-LCA method is confirmed by detailed numerical results.

Explore related subjects

ElectroencephalographyEvoked PotentialsEvoked Potentials, Auditory, Brain StemFourier AnalysisHumansSignal Processing, Computer-AssistedJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

X H Yu, Y S Zhang, Z Y He. 1994. Peak component latency-corrected average method for evoked potential waveform estimation.. https://doi.org/10.1109/10.335845

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Serum neuron-specific enolase in the major subtypes of status epilepticus.

OBJECTIVES: To determine the relative magnitudes of neuron-specific enolase (NSE) levels after complex partial status epilepticus (SE), absence SE, generalized convulsive SE, and subclinical generalized convulsive SE (frequently referred to as acute symptomatic myoclonic status epilepticus). BACKGROUND: NSE is a marker of acute brain injury and blood-brain barrier dysfunction, which is elevated in SE. METHODS: Serum NSE levels were drawn in 31 patients 1, 2, 3, and 7 days after SE. Patients were classified as acute symptomatic or remote symptomatic, and the duration and outcome of SE were determined and correlated with the peak NSE level. RESULTS: NSE was elevated significantly in all four subtypes of SE, but NSE levels were highest in complex partial and subclinical SE. The mean peak NSE level for the complex partial SE group was 23.88 ng/mL (n = 12), 21.5 ng/mL for absence SE (n = 1), 14.10 ng/mL for the generalized convulsive SE group (n = 12), and 37.83 ng/mL for the subclinical SE group (n = 6), all of which was significantly higher than normal control subjects (5.02 ng/mL). Outcome was significantly different between the three groups (p = 0.0007), and was significantly worse for subclinical SE (p = 0.0005, subclinical versus generalized convulsive SE). CONCLUSION: Serum NSE levels were highest in complex partial and subclinical generalized convulsive SE. The extremely high levels of NSE in subclinical SE reflect the severity of the acute neurologic insults and poor outcome common to subclinical SE. High NSE levels in complex partial SE reflects the long duration of SE in this subgroup, and potential for brain injury.

Electroencephalography↗